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Abstract
Background
Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a nuclear receptor that mod-
ulates inflammation in models of asthma. To determine whether pioglitazone improves mea-
sures of asthma control and airway inflammation, we performed a single-center
randomized, double-blind, placebo-controlled, parallel-group trial.
Methods
Sixty-eight participants with mild asthma were randomized to 12 weeks pioglitazone (30 mg
for 4 weeks, then 45mg for 8 weeks) or placebo. The primary outcome was the adjusted
mean forced expiratory volume in one second (FEV1) at 12 weeks. The secondary outcomes
were mean peak expiratory flow (PEF), scores on the Juniper Asthma Control Questionnaire
(ACQ) and AsthmaQuality of Life Questionnaire (AQLQ), fractional exhaled nitric oxide
(FeNO), bronchial hyperresponsiveness (PD20), induced sputum counts, and sputum super-
natant interferon gamma-inducible protein-10 (IP-10), vascular endothelial growth factor
(VEGF), monocyte chemotactic protein-1 (MCP-1), and eosinophil cationic protein (ECP) lev-
els. Study recruitment was closed early after considering the EuropeanMedicines Agency’s
reports of a potential increased risk of bladder cancer with pioglitazone treatment. Fifty-five
cases were included in the full analysis (FA) and 52 in the per-protocol (PP) analysis.
Results
There was no difference in the adjusted FEV1 at 12 weeks (-0.014 L, 95% confidence inter-
val [CI] -0.15 to 0.12, p = 0.84) or in any of the secondary outcomes in the FA. The PP analy-
sis replicated the FA, with the exception of a lower evening PEF in the pioglitazone group
(-21 L/min, 95% CI -39 to -4, p = 0.02).
Conclusions
We found no evidence that treatment with 12 weeks of pioglitazone improved asthma con-
trol or airway inflammation in mild asthma.
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Introduction
Asthma is a common and chronic condition that affects 235 million people worldwide and is
responsible for substantial healthcare expenditures [1]. Inhaled corticosteroids and bronchodilators
are the mainstay of asthma pharmacotherapy. Although these treatments are highly effective, many
patients fail to achieve optimal asthma control and are at risk of impaired quality of life, recurrent
exacerbations, and even death. In some patients, these outcomes are due to poor concordance with
medication, while others dislike or exhibit reduced responses to inhaled medications, creating a
need to identify novel therapeutic targets if the burden of asthma is to be reduced.
The nuclear transcription factor peroxisome proliferator-activated receptor gamma
(PPAR-γ) is an important regulator of cellular homeostasis and energy metabolism that also
has anti-inflammatory properties [2–7]. There is evidence that PPAR-γ is involved in inflam-
mation and airway remodeling responses in asthma [4]. In experimental models of asthma,
the activation of PPAR-γ suppresses the increase in airway hyperresponsiveness, eosinophil
influx, and expression of Th-2 cytokines that occur in the lung following an allergen chal-
lenge [5, 6, 8–10].
PPAR-γ is thought to exert its immune modulating effects by reducing the downstream
gene transcription of targets of the pro-inflammatory transcription factors activator protein-1
(AP-1) and nuclear factor-kappaB (NF-kB) [11–13]. In cultured human airway smooth muscle
cells (HASMs), PPAR-γ activation suppresses the release of the chemokines MCP-1 (monocyte
chemotactic protein-1/CCL2) and eotaxin (CCL11) in response to the potent inflammatory
stimulant tumor necrosis factor-alpha (TNF-α) [3]. This suppression of eotaxin release is sec-
ondary to reduced histone acetylation and reduced binding of NF-kB to the eotaxin promoter,
reducing gene transcription [3].
The PPAR-γ agonists pioglitazone and rosiglitazone were developed to treat the hyperglyce-
mia and insulin resistance of type 2 diabetes mellitus, and were used widely until rosiglitazone
was withdrawn due to an adverse cardiovascular safety profile [14–16]. Prior to its withdrawal,
rosiglitazone had been studied in two short-term (up to 28 days) randomized controlled trials
(RCTs) in asthma that found modest effects on the late asthmatic reaction and airway obstruc-
tion in smokers with asthma [17, 18]. A longer term study of pioglitazone in a subset of obese
subjects with poorly controlled asthma resulted in no significant improvement in measures of
asthma control [19]. The aim of the present study was to test the hypothesis that the activation
of PPAR-γ with pioglitazone (which has a more favorable safety profile than that of rosiglita-
zone) would improve measures of asthma control and markers of airway inflammation over a
12-week period in mild asthma. Study recruitment was terminated after 68 participants had
been recruited after reports emerged that pioglitazone treatment may be associated with an
increased risk of developing bladder cancer [20].
Materials and Methods
Ethics statement
The study was approved by Nottingham Research Ethics Committee 2 (08/H0408/120) and the
Medicines and Healthcare Products Regulatory Agency (MHRA) (08028). All participants pro-
vided written informed consent. Trial registration: NCT01134835.
Clinical Trial of Pioglitazone in Asthma
PLOSONE | DOI:10.1371/journal.pone.0160257 August 25, 2016 2 / 15
was approved by Nottingham Research Ethics
Committee 2. There was no further input from the
sponsors into the analysis, interpretation, or
preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Study design and participants
A single-center randomized, double-blind, placebo-controlled, parallel-group trial comparing
pioglitazone and placebo over 12 weeks in adults with mild asthma was performed at City Hos-
pital, Nottingham, UK. The study design was approved by Nottingham Research Ethics Com-
mittee 2 (08/H0408/120). All participants gave written informed consent. The full trial
protocol is given in S1 Text.
Potential participants aged 18–75 years with a clinical diagnosis of asthma who were taking
0–800 μg of inhaled beclomethasone dipropionate (or equivalent) and short-acting β2-agonists
(SABAs) as required were identified from primary care practices and our research database
between January 2010 and February 2012. At screening, participants were required to have a
post-bronchodilator forced expiratory volume in one second (FEV1) 60% of predicted
with 12% reversibility of the pre-bronchodilator FEV1 with 400 μg of salbutamol or 12%
peak flow variability during the run-in period (maximum peak expiratory flow [PEF] minus
minimum PEF divided by average PEF) to be eligible.
The exclusion criteria included an exacerbation of asthma within six weeks, current smoking,
or a history of more than 10 pack years of smoking, or treatment with leukotriene antagonists,
long-acting beta-agonists, theophylline, or oral steroids. Patients with a history of diabetes or
liver or cardiovascular disease; patients who were pregnant, lactating, or not using adequate con-
traception; or patients with contraindications to pioglitazone were excluded for safety reasons.
Screening visit. FEV1 was measured as the greater of two values within 100 ml using a dry
bellows spirometer (Vitalograph, Buckingham, UK), prior to and 15 minutes after the inhala-
tion of 400 μg of salbutamol via a spacer (VolumaticTM, Allen & Hanburys Ltd, Middlesex,
UK). Sputum induction with hypertonic saline was performed as described previously [21, 22]
using the ultrasonic nebulizer OMRON NE-U17 (OMRON Health Care Ltd, Milton Keynes,
UK). A clinician reviewed and examined participants at each visit.
Run-in period. Participants entered a two-week run-in period, during which morning
and evening PEF (Mini-Wright, Clement Clarke International Ltd, Harlow, UK) and asthma
medication use were recorded.
Randomization. Eligible participants were randomized to 12 weeks pioglitazone (30 mg
once a day for 4 weeks, then 45 mg once a day for 8 weeks) or matched placebo using an inter-
net-based randomization schedule stratified by inhaled corticosteroid use. The allocation
sequence was generated using random permuted blocks of two, four, and six and maintained
on a secure server by the Nottingham Clinical Trials Unit (CTU).
The baseline clinical measurements were: the fractional exhaled nitric oxide (FeNO) in
parts per billion (ppb) at 50 mL/second (NIOX1 Flex, Aerocrine, Solna, Sweden), pre-bron-
chodilator FEV1, airway hyperresponsiveness to methacholine (PD20, Ganshorn ProvoJet,
Ganshorn Medizin Electronic GmbH, Niederlauer, Germany) based on the protocol of Yan,
Asthma Control Questionnaire (ACQ), Asthma Quality of Life Questionnaire (AQLQ), and
induced sputum [23–25]. Study visits were at same time of day +/- 1.5 hours at 4, 8, 12, and 16
weeks within three days of the protocol date and the baseline clinical measurements were
repeated after 12 weeks of treatment.
Study intervention. Pioglitazone tablets were over encapsulated with DBcaps1 capsules
(Capsugel Belgium NV, Bornem, Belgium), and a matched placebo backfilled with lactulose
was manufactured by Catalent Pharma Solutions, Bolton, UK. An independent pharmacist
issued 30 capsules of the study medication to each participant every four weeks and compliance
was assessed by counting the returned capsules. All participants and clinical investigators per-
forming the clinical assessments were blinded to allocation until all trial procedures were per-
formed and the analysis was complete.
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Outcome measures and statistical analysis. The primary outcome measure was the
adjusted mean FEV1 at 12 weeks compared between treatment groups by analysis of covariance
(ANCOVA) incorporating terms for baseline value, treatment arm, inhaled corticosteroid use,
age, gender, and height. The secondary outcome measures at 12 weeks included mean morning
and evening PEF for 14 days prior to the study visit, ACQ and AQLQ scores, FeNO, PD20,
SABA use, and body mass index (BMI). We considered a PD20 of 800 μg to be equivalent to a
PC20 of 8 mg/mL [26]. Final follow up visits were in December 2011.
In subsets of participants, induced sputum cell counts, sputum supernatant interferon
gamma-inducible protein-10 (CXCL10/IP-10), vascular endothelial growth factor (VEGF),
MCP-1/CCL2, and eosinophilic cationic protein (ECP) were measured. Activation of PPAR-γ
was assessed by comparing levels of cytoplasmic and nuclear PPAR-γ from induced sputum
cells between groups. Adverse effects (reported spontaneously at clinic visits and on diary
cards) were recorded, and random glucose, full blood count (FBC), and liver function tests
(LFTs) were measured pre- and post-treatment.
Where appropriate, secondary endpoints were log-transformed to approximate a normal
distribution (PD20, percentage eosinophil count, and FeNO) and compared between groups
using ANCOVA, incorporating terms for baseline value treatment arm, inhaled corticosteroid
use, and, where appropriate, age, gender, and height. Values that could not be transformed
were compared using the Mann-Whitney U test. In participants with values below the lower
limit of detection in laboratory assays (five participants for ECP), a value of 0.5 of the lower
detection limit was used. Sputum mediators were expressed per 1 x 106 cells and were reported
as geometric means with 95% confidence intervals (CIs). Stata v11.0 (StataCorp LP, College
Station, TX, USA) and GraphPad Prism Version 6 (GraphPad Software, La Jolla, CA, USA)
were used to perform the statistical analyses.
The a priori calculation suggested that 88 participants would allow us to detect a difference
of 150 mL between groups in the mean FEV1 at 12 weeks, with 80% power at a 5% two-sided
significance level, assuming a standard deviation (SD) of FEV1 over eight weeks of 250 mL
[27].
A Trial Steering Committee (TSC) and independent Data Monitoring and Ethics Commit-
tee (DMEC) monitored the progress and safety of the trial.
Sputum processing. Induced sputum samples were processed within two hours of induc-
tion as described previously [21, 22]. Sputum supernatant IP-10, MCP-1, and VEGF were
assayed using the Bio-Plex1 200 system (Bio-Rad, Hemel Hempstead, UK) and supernatant
ECP was assayed using ImmunoCAP 100 (Phadia AB, Uppsala, Sweden) according to the man-
ufacturers’ instructions. PPAR-γ was assayed in the nuclear and cytoplasmic fractions of spu-
tum cells using a TransAM™ PPAR-γ Kit (Active Motif, Rixensart, Belgium) and a competitive
enzyme-linked immunosorbent assay (ELISA) PPAR-γ kit (Biosources, Inc., San Diego, CA,
USA) according to the manufacturers’ instructions. The optical density at 450 nm (OD450) was
used for quantification of nuclear PPAR-γ and the reciprocal of the OD450 was used for quanti-
fication of cytoplasmic PPAR-γ.
Results
Of the 119 individuals screened, 68 participants were randomized, 34 to pioglitazone and 34 to
placebo between January 2010 and February 2012 (Fig 1). The full trial dataset is given in S1
Data and Consort checklist in S2 Text.
The full analysis was performed on 55 completed cases, and after excluding those with pro-
tocol deviations, the per-protocol analysis included 52 participants. The baseline characteristics
of the study population are shown in Table 1. Subjects were well matched between treatment
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Fig 1. Consort participant flow.
doi:10.1371/journal.pone.0160257.g001
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Table 1. Baseline demographics.
All PIOGLITAZONE PLACEBO
Number of observations n = 68 n = 34 n = 34
Age (years) 54.4 ± 13.6 51.6 ± 13.2 57.3 ± 13.7
• GenderMale n
• (%)Female n (%)
• 37 (54.4%)31
(45.6%)
• 18(52.9%)16
(47.1%)
• 19(55.9%)
• 15 (44.1%)
• EthnicityWhite n (%)Other (%) • 67(98.5)1(1.5) • 33(97.01%)1
(2.9%)
34 (100%)
Body mass index (kg/m2)† 27.5 ± 3.6 28.1 ± 4.0 26.9 ± 3.0
History of smoking (Pack years)Median (range) 0 (0,10) 0.1 (0,10) 0 (0,10)
Daily inhaled steroid Yes (%)No (%) 51 (75%)17 (25%) 26 (76.5%)8 (23.5%) 25 (73.5%)9
(26.5%)
Daily inhaled corticosteroid dose (beclomethasone diproprionate equivalent [mcg/
day])Median (interquartile range)
200 (0, 400) 300 (200, 400) 200 (0, 400)
Duration of asthma (years)Median (interquartile range) 28.5 (18, 45.5) 27 (19, 41) 30.5 (13, 46)
Pre-bronchodilator FEV1 (liters) 2.70 ± 0.74 2.75 ± 0.73 2.65 ± 0.75
Predicted FEV1 (%) 90 ± 15.5 92 ± 15.5 88 ± 15.6
FVC (liters) 3.84 ± 1 3.92 ± 1 3.76 ± 1
Predicted FVC (%) 105.1 ± 15.7 107.8 ± 14.3 102.3 ± 16.8
FEV1/FVC (%) 70.90 ± 9.6 71 ± 10.6 70.8 ± 8.6
FEV1 reversibility at screening¶ (%)Median (interquartile range) 11.3 (7, 15)† 11.5 (7, 15) 11.3 (6.0, 17.0)‡
Exhaled nitric oxide FeNO at 50 ml ﬂow (ppb)Geometric mean (95% CI) 24.9 (21.1, 29.4) 26.6 (20.6, 34.5) 23.20 (18.7, 28.8)
Airway hyperresponsiveness to methacholine PD20 FEV1 (mcg)*Geometric mean
(95% CI)
97.7 (59.9, 159.5) 86.5 (39.3, 190.1)
R
109.3 (56.7,
219.3)
R R
Juniper ACQ# score at baseline 0.9 ± 0.4~ 1.0 ± 0.7 0.9 ± 0.41
Juniper AQLQ+ score at baseline 6.2 ± 0.4~ 6.1 ± 0.6 6.2 ± 0.61
Meanmorning peak expiratory ﬂow1 392 ± 95 391 ± 96 392 ± 95
Mean evening peak expiratory ﬂow2 396 ± 97 399 ± 93 396 ± 97
Peak expiratory ﬂow variability^ (%)Median (interquartile range) 19 (15, 24) 18 (13, 27) 18 (15, 23)
Short-acting beta2-agonist use during run-in (actuations/day) 0.7 ± 1 1.5 ± 1.8 0.7 ± 1
Sputum differential eosinophil count % Geometric mean (95% CI)δ 0.8 (0.5, 1.4) 1.2 (0.6, 2.5) 0.5 (0.2, 1.1)
Arithmetic mean values reported as mean unless speciﬁed
± Standard deviation
Geometric means are reported with a 95% conﬁdence Interval (CI)
* PD20-The provocative dose of methacholine (in micrograms) that results in a 20% fall in the FEV1, available in 46 participants at baseline and post-
treatment. A PD20 of 100 mcg is equivalent to a PC20 of 1 mg/mL
¶ The percentage change in the pre-bronchodilator FEV1 15 minutes after 200 mcg of inhaled salbutamol
+ Juniper Asthma Control Questionnaire- A validated questionnaire providing a numerical assessment of asthma control over the preceding 7 days. The
mean score ranges from 0 (fully controlled) to 6 (poorly controlled).
# Juniper Asthma Quality of Life Questionnaire-The standardized 32-question AQLQ assesses the impact of asthma on 4 domains: symptoms, activity
limitation, emotional function, and environmental stimuli. Mean score ranges from 1 (impaired quality of life) to 7 (no impairment of quality of life).
1 and 2 The mean peak expiratory ﬂow calculated from the 14-day run-in period
^Peak expiratory ﬂow variability calculated as the difference between the highest and lowest peak expiratory ﬂow expressed as a percentage of the mean
peak expiratory ﬂow calculated from the 14-day run-in period
FEV1- Forced expiratory volume in one second. FVC- Forced vital capacity. ppb- Parts per billion
† n = 68
‡ n = 34
R
n = 22
R R
n = 24
1 n = 32
~ n = 66
δ n = 41 (23 pioglitazone and 18 placebo)
doi:10.1371/journal.pone.0160257.t001
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arms, 75% were taking inhaled corticosteroids with a SABA, and 25% were taking a SABA
alone. Forty-one participants produced viable induced sputum samples pre- and post-treat-
ment (Tables 1 and 2). Medication adherence assessed by tablet counting was greater than 95%
in both groups over the course of the study.
Closure of recruitment
The EuropeanMedicines Agency (EMA) reported that pioglitazone may be associated with an
increased risk of developing bladder cancer in July 2011 (20). Because there were no proven bene-
fits associated with taking pioglitazone in asthma, the TSC concluded that the risk to benefit ratio
had become unacceptable for participants with mild asthma and recruitment was stopped on 14
October, 2011. At that point, 68 of the minimum requirement of 88 participants had been ran-
domized, with 52 participants having completed the study and 10 still in the treatment phase of
the study. Among those still participating in the study, 70% withdrew after receiving notification
of the EMA report, while three participants elected to complete the study. All participants and
investigators remained blinded to allocation until the analysis was completed.
Efficacy
There was no significant difference observed in the primary outcome measure, the adjusted
mean FEV1 at 12 weeks, between the pioglitazone and placebo groups (adjusted mean differ-
ence -0.014 L, 95% CI -0.15 to 0.12, p = 0.84). In the FA there were no differences in any of the
secondary outcomes between the groups at 12 weeks, although there was a trend toward a
lower adjusted mean morning PEF (-16 L/min 95% CI -33 to 2, p = 0.075) and evening PEF
(-17 L/min, 95% CI -35 to 1, p = 0.068) in the pioglitazone group. There was also a trend
toward a higher use of as required SABA use in the pioglitazone group (0.6 actuations/day,
95% CI -0.05 to 1.2, p = 0.07) (Fig 2 and Table 3).
The per protocol analysis replicated the full analysis, except that the mean evening PEF was
significantly lower in the pioglitazone group after 12 weeks (-21 L/min, 95% CI -39 to -4,
p = 0.02) (Table 4).
Table 2. Induced sputum indices at baseline.
Mean (SD) n = 41 PIOGLITAZONE n = 23 PLACEBO n = 18
All n = 23 SABA = 7 ICS = 16 n = 18 SABA = 6 ICS = 12
Sputum total cell count ×106/g 1.1 ± 1.7 1.0 ± 1.2 1.3 ± 1.4±
1.4
0.9 ± 1.2 1.3 ± 2.6 0.6 ± 0.4 1.7 ± 2.6
Sputum differential neutrophil count % 49.0 ± 26.1 47.3 ± 26.3 64.6 ± 20.7 39.7 ± 25.4 51.2 ± 26.3 46.3 ± 35.4 53.6 ± 22
Sputum differential eosinophil count%Geometric
mean (95% CI)¶
0.8 (0.5,
1.4)
1.2 (0.6,
2.5)
0.4 (0.08,
2.4)
1.8 (0.8,
4.2)
0.5 (0.2,
1.1)
0.4 (0.07,
2.4)
0.5 (0.2,
1.5)
Sputum differential macrophage count% 43.1 ± 26.0 41.8 ± 27.1 29.2 ± 20 47.4 ± 28.5 44.6 ± 25.3 47.8 ± 32.9 43.0 ± 22.0
Sputum differential lymphocyte count% 0.6 ± 0.6 0.7 ± 0.7 0.8 ± 1.0 0.6 ± 0.6 0.4 ± 0.4 0.4 ± 0.4 0.4 ± 0.4
Sputum differential epithelial cell count% 3.9 ± 4.9 5.0 ± 5.5 3.9 ± 3.8 5.5 ± 6.1 2.4 ± 3.6 4.2 ± 5.7 1.5 ± 1.7
Sputum squamous contamination% 4.2 ± 4.1 4.5 ± 4.8 4.0 ± 4.1 4.7 ± 5.2 3.9 ± 3.2 4.10 ± 2.0 3.8 ± 3.7
Values reported as arithmetic mean unless speciﬁed
± Standard deviation
¶ Geometric mean reported with a 95% conﬁdence interval (CI)
SABA- Short-acting β2-agonist
ICS- Inhaled corticosteroid
doi:10.1371/journal.pone.0160257.t002
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In subsets of participants that provided induced sputum samples pre- and post-treatment,
there were no significant differences in the induced sputum differential cell counts or the
induced sputum supernatant ECP, MCP-1, IP-10, or VEGF, or the nuclear and cytoplasmic
levels of PPAR-γ between groups (Figs 2 and 3).
There was an increase in the reporting of expected side effects of pioglitazone in the active
group, particularly ankle swelling, weight gain, insomnia, and lethargy (Table 5). There were
no asthma exacerbations requiring oral corticosteroids or hospital admission in the study;
however, five participants in the pioglitazone group and two in the placebo group reported
mild/moderate asthma exacerbations that required an increase in SABAs.
The pioglitazone-treated group had a significantly lower adjusted mean hemoglobin (-0.51
g/dL, 95% CI -1 to -0.1, p = 0.015), red cell count (-0.2 x 1012/L, 95% CI -0.03 to -0.04,
p = 0.012) and adjusted mean cell hemoglobin (-0.6 g/dL, 95% CI -1.1 to -0.08, p = 0.024) com-
pared with the placebo-treated group at week 12 (Fig 2 and Table 6).
Discussion
In this randomized controlled trial, the administration of pioglitazone for 12 weeks in mild
asthma did not result in any improvements in a range of markers of asthma control or
Fig 2. Efficacy analysis. The adjusted mean of the secondary clinical outcomes at 12 weeks was compared
between groups using ANCOVA including terms for baseline value, treatment arm, inhaled corticosteroid
use, age, gender, and height and expressed as the difference in the adjusted means with a 95% confidence
interval (CI). FEV1- Forced expiratory volume in one second. FeNO–Fractional exhaled nitric oxide. ppb—
Parts per billion. PD20—The provocative dose of methacholine (in micrograms) that results in a 20% fall in the
FEV1, available in 46 participants at baseline and post-treatment. A PD20 of 100 mcg is equivalent to a PC20
of 1 mg/mL. Fold difference units—antilog of the (adjusted mean difference) with 95% confidence interval. A
1-fold change is equivalent to 0 doubling doses. The mean peak flow calculated from the 14 days prior to the
week 12 visit. ACQ—Juniper Asthma Control Questionnaire—A validated questionnaire providing a
numerical assessment of asthma control over the preceding 7 days. The mean score ranges from 0 (fully
controlled) to 6 (poorly controlled). AQLQ—Juniper Asthma Quality of Life Questionnaire—The standardized
32-question AQLQ assesses the impact of asthma on 4 domains: symptoms, activity limitation, emotional
function, and environmental stimuli. Mean score ranges from 1 (impaired quality of life) to 7 (no impairment of
quality of life). SABA–Short acting beta2 agonist. Induced sputum data available for 41 participants in the full
analysis.
doi:10.1371/journal.pone.0160257.g002
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measures of airway inflammation. In fact, we observed a lower post-treatment mean evening
PEF and a trend toward higher SABA reliever use in the pioglitazone group, which was not
accompanied by significant deterioration in asthma control or scores on quality of life ques-
tionnaires. Although these findings most likely reflect the multiplicity of analyses, they could
have been caused indirectly by side effects of pioglitazone such as insomnia and fatigue. If the
reduction in PEF is a true effect, and assuming a minimum important difference (MID) for
PEF of 15 to 20 L/minute, this is of a magnitude that could have been perceived by the partici-
pants [28].
Table 3. Full analysis.
PIOGLITAZONE n = 27 PLACEBO n = 28
Baseline (SD) Week 12 Adjusted
mean at 12
weeks (95%
CI)
Baseline Week 12 Adjusted
mean at 12
weeks
Adjusted difference
in means at 12
weeks between
group(95% CI)
p-value
(95% CI)
FEV1 (liters) 2.71 ± 0.82.71 2.75 ± 0.82.75 2,67 (2.58,
2.76)
2.59 ± 0.82.59 2.61 ± 0.82.61 2.69 (2.60,
2.78)
-0.014 (-0.15, 0.12)-
0.014
0.84
Exhaled nitric oxide FeNO (ppb)¶
geometric mean (95% CI)
31.6 (24, 41.7) 24.0 (18.6,
30.2)
21.9 (18.2,
26.3)
23.4 (18.2,
29.5)
24.6 (19.5,
31.6)
26.6 (22.1,
31.8)
0.8 (0.6, 1.1) 0.18
Airway hyperresponsiveness to
methacholine PD20 FEV1*mcg.
Adjusted difference fold difference
units^ (95% CI)
86.5 (38.9,
190.6)
114.8 (55,
239.9)
129.2 (74.1,
223.9)
109.3 (56.7,
210.9)
128 (57.5,
284.8)
114.4 (67.6,
195)
1.1^ (0.1, 2.6) 0.77
Mean morning PEF1 (L/min) 385 ± 99 388 ± 106 388 (376, 400) 392 ± 99 404 ± 109 404 (392,
416)
-16 (-35, 2) 0.075
Mean evening PEF2 (L/min) 393 ± 96 394 ± 107 390 (379, 402) 395 ± 101 404 ± 108 407 (395,
419)
-17 (-35, 1) 0.068
Juniper ACQ+ 1.1 ± 0.7 0.7 ± 0.5 0.7 (0.5, 0.9) 0.9 ± 0.3 0.7 ±0.5 0.7 (0.5, 0.9) 0.03 (-0.3, 0.3) 0.86
Juniper AQLQ# 6.0 ± 0.7 6.3 ± 0.6 6.3 (6.1, 6.5) 6.1 ± 0.6 6.3 ±0.6 6.3 (6.1, 6.4) 0.01 (-0.2, 0.6) 0.94
Short-acting beta2-agonist use in the
14 days preceding week 12
(actuations/day)
1.7 ± 1.8 1.1 ± 1.5 1.1 (0.7, 1.4) 0.8 ± 1 0.4 ±0.5 0.5 (0.1, 0.9) 0.6 (-0.05,1.2) 0.07
Body mass index at week 12 (kg/m2) 27.5 ± 3.1 27.8 ± 3.1 27.4 (27.1,
27.6)
26.8 ± 3.2 26.9 ±3.3 27.3 (27,
27.6)
0.06 (-0.4, 0.5) 0.76
Values are reported as arithmetic mean unless speciﬁed
± Standard deviation
¶ Geometric means are reported with a 95% conﬁdence interval (CI)
The adjusted mean of the secondary clinical outcomes at 12 weeks was compared between groups using ANCOVA including terms for baseline value,
treatment arm, inhaled corticosteroid use, age, gender, and height and expressed as the difference in the adjusted means with a 95% conﬁdence interval
(CI) and p-value
*PD20-The provocative dose of methacholine (in micrograms) that results in a 20% fall in the FEV1, available in 46 participants at baseline and post-
treatment.
A PD20 of 100 mcg is equivalent to a PC20 of 1 mg/ml
^Fold difference units- antilog of the (adjusted mean difference) with 95% CI. A 1 fold change is equivalent to 0 doubling doses
+ Juniper Asthma Control Questionnaire- A validated questionnaire providing a numerical assessment of asthma control over the preceding 7 days. The
mean score ranges from 0 (fully controlled) to 6 (poorly controlled).
# Juniper Asthma Quality of Life Questionnaire-The standardized 32-question AQLQ assesses the impact of asthma on 4 domains: symptoms, activity
limitation, emotional function, and environmental stimuli. Mean score ranges from 1 (impaired quality of life) to 7 (no impairment of quality of life).
1 and 2 The mean peak ﬂow calculated from the 14 days prior to the week 12 visit
FEV1- Forced expiratory volume in one second
FVC- Forced vital capacity
ppb- Parts per billion
FEV1- Forced expiratory volume in one second
ANCOVA- Analysis of covariance
doi:10.1371/journal.pone.0160257.t003
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Despite evidence that PPAR-γ activation has anti-inflammatory effects in experimental
models of asthma, there are a number of potential reasons why pioglitazone may not have
exerted an effect in the present study. Firstly, the early closure of recruitment limited the num-
ber of participants completing the study, leaving the study underpowered to detect a difference
of 150 ml between groups. However, considering the narrow 95% CIs for the difference in
FEV1, the lack of change in airway hyper-responsiveness, lower PEF, and trend toward higher
SABA use in the pioglitazone group, it is unlikely that we missed a clinically important effect
on airway dysfunction in mild asthma.
It is possible that the observed lack of efficacy was because pioglitazone was not biologically
active. Although we did not measure plasma levels of pioglitazone, more than 95% of the study
Table 4. Per-protocol analysis.
PIOGLITAZONE n = 27 PLACEBO n = 28
Baseline
(SD)
Week 12 Adjusted mean
at 12 weeks
(95% CI)
Baseline Week 12 Adjusted
mean at 12
weeks
Adjusted difference in
means at 12 weeks
between group (95% CI)
p-value
(95% CI)
FEV1 (liters) 2.76 ± 0.8 2.80 ± 0.8 2.68 (2.59, 2.78) 2.58 ± 0.8 2.60 ± 0.8 2.71 (2.61,
2.81)
-0.03 (-0.17, 0.12) 0.71
Exhaled nitric oxide FeNO (ppb)¶ geometric
mean (95% CI)
32.7 (25,
42.8)
23.8 (18.5,
30.5)
22.2 (18.3, 27) 25.1 (19.8,
31.8)
25.9 (20.4,
33.1)
27.9 (22.8,
33.6)
0.8 (0.6, 1.1) 0.14
Airway hyperresponsiveness to
methacholine PD20 FEV1* Adjusted
difference in means fold difference units
(95% CI)
87.8 (38,
201)
114.2
(52.5,
248.3)
123.2 (71.3,
212.9)
106.3 (53,
213.3)
133.6
(56.6,
315.5)
124.2 (72.9,
211.7)
1.0^ (0.4, 2.3) 0.98
Mean morning PEF1 (L/min) 389 ± 99 393 ± 105 390 (378, 402) 393 ± 99 406 ± 110 409 (396,
421)
-19 (-38, 0.3) 0.053
Mean evening PEF2 (L/min) 397 ± 95 399 ± 106 391 (379, 402) 393 ± 98 404 ± 109 412 (400,
424)
-21 (-39, 4) 0.02
Juniper ACQ+ 1.1 ± 0.7 0.7 ± 0.6 0.7 (0.6, 0.9) 0.9 ± 0.3 0.6 ± 0.4 0.6 (0.4, 0.7) 0.2 (-0.1, 0.4) 0.23
Juniper AQLQ# 6.0 ± 0.7 6.3 ± 0.6 6.3 (6.2, 6.5) 6.3 ± 0.4 6.4 ± 0.5 6.4 (6.2, 6.5) -0.1 (-0.3, 0.2) 0.69
Short-acting beta2-agonist use in the 14
days preceding week 12 (actuations/day)
1.6 ± 1.7 1.0 ± 1.4 1.0 (0.6, 1.4) 0.8 ± 1.0 0.4 ± 0.5 0.4 (0.2,0.80) 0.6 (-0.01, 1.2) 0.055
Body mass index at week 12 (kg/m2) 27.3 ± 2.9 27.5 ± 2.9 27.3 (27, 27.5) 26.8 ± 3.24 26.8 ± 3.3 27.1 (26.8,
27.4)
0.1 (-0.3, 0.6) 0.51
Values are reported as arithmetic mean unless speciﬁed
± Standard deviation
¶ Geometric means are reported with a 95% conﬁdence interval (CI)
The adjusted mean of the secondary clinical outcomes at 12 weeks was compared between groups using ANCOVA including terms for baseline value,
treatment arm, inhaled corticosteroid use, age, gender, and height and expressed as the difference in the adjusted means with a 95% conﬁdence interval
(CI) and p-value.
*PD20-The provocative dose of methacholine (in micrograms) that results in a 20% fall in the FEV1, available in 43 participants at baseline and post-
treatment.
A PD20 of 100 mcg is equivalent to a PC20 of 1 mg/mL.
^Fold difference units- antilog of the (adjusted mean difference) with 95% CI. A 1-fold change is equivalent to 0 doubling doses.
+ Juniper Asthma Control Questionnaire- A validated questionnaire providing a numerical assessment of asthma control over the preceding 7 days. The
mean score ranges from 0 (fully controlled) to 6 (poorly controlled).
# Juniper Asthma Quality of Life Questionnaire-The standardized 32-question AQLQ assesses the impact of asthma on 4 domains: symptoms, activity
limitation, emotional function, and environmental stimuli. Mean score ranges from 1 (impaired quality of life) to 7 (no impairment of quality of life).
1 and 2 The mean peak ﬂow calculated from the 14 days prior to the week 12 visit
FEV1- Forced expiratory volume in one second
FVC- Forced vital capacity
ppb- Parts per billion
FEV1- Forced expiratory volume in one second
ANCOVA- Analysis of covariance
doi:10.1371/journal.pone.0160257.t004
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Fig 3. Mechanistic endpoints. In subsets of participants, the following assays were performed: Cytoplasmic
PPAR-γ transcription factor assay. Pioglitazone n = 6, placebo n = 6. Mean of the reciprocal OD450. IP-10,
MCP-1, VEGF and levels in sputum supernatant, assay (Bio-Plex) pg/mL normalized to 1 x 106 sputum cells.
Pioglitazone n = 11, placebo n = 8. ECP pioglitazone n = 10 (total ECP n = 18) Phadia ImmunoCAP
normalized to 1 x 106 sputum cells. PPAR-γ- Peroxisome proliferator-activated receptor gamma. OD Optical
density (spectrophotometry). IP-10- Interferon gamma-inducible protein-10. VEGF- Vascular endothelial
growth factor. MCP-1- Monocyte chemotactic protein-1. ECP- Eosinophil cationic protein.
doi:10.1371/journal.pone.0160257.g003
Table 5. Reported adverse events occurring in more than 1 participant by system.
PIOGLITAZONE PLACEBO
Respiratory system
Upper respiratory tract infection 8 8
Exacerbation of asthma (mild/moderate) 5 2
Blood and lymphatic disorders
Thrombocytopenia 2 0
Leukopenia or Neutropenia 1 1
Nervous system disorders
Insomnia 5 1
Alteration of mood 3 0
Headache 1 4
Eye disorders
Hordeolum 2 0
Ear and labyrinth disorders
Epistaxis 2 1
Vertigo 0 2
Renal tract
Urinary tract infection 0 2
Musculoskeletal system
Arthralgia 1 1
General disorders
Ankle edema (spontaneously reported) 8 2
Weight gain (spontaneously reported) 4 0
Fatigue 3 0
Investigations
Weight increased (> 5% of baseline) 3 1
doi:10.1371/journal.pone.0160257.t005
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capsules were taken by participants and we observed a decrease in hemoglobin, a recognized
systemic side effect of pioglitazone [29–31]. However, despite evidence of systemic biological
activity, we were unable to confirm that pioglitazone successfully activated PPAR-γ in the
lungs to induce nuclear translocation of PPAR-γ within the induced sputum cells. As pioglita-
zone is highly bound to plasma proteins (>99%) and has a low volume of distribution across
tissues, it may not have entered the airways in sufficient concentration to exert an effect.
An alternative explanation for the lack of efficacy is that the study participants had adequate
asthma control with low levels of eosinophilic airway inflammation and preserved lung func-
tion at baseline, leaving little potential for improvement. Recruiting patients with evidence of
eosinophilic inflammation would have been better but would have rendered recruitment into
the study even more difficult. Therefore, we have not excluded a possible anti-inflammatory
effect in patients with more severe asthma and more marked airway inflammation, and a study
with longer duration in this cohort would be required to assess the effect of pioglitazone on the
risk of asthma exacerbations.
Table 6. Safety set blood test monitoring.
PIOGLITAZONE PLACEBO
Baseline
n = 34 (SD)
Week 12
(n = 28)
Week 12
adjusted mean
n = 27 (95% CI)
Baseline
n = 34 (SD)
Week 12
(n = 29)
Week 12
adjusted mean
(95%CI)
Difference in adjusted
means between
groups at 12 weeks
p-value
(95% CI)
Hemoglobin (g/dL) 13.9 ± 1.2 13.3 ± 1.3 13.5 (13.2, 13.8) 14.3 ± 1.1 14.3 ± 1.1 14.1 (13.8,
14.3)
-0.51 (-1, -0.1) 0.015*
Hematocrit 0.4 ± 0.03 0.41 ± 0.03 0.4 (0.4,0.4) 0.4 ± 0.02 0.4 ± 0.03 0.4 (0.4, 0.4) -0.01 (-0.03, 0.0003) 0.056
Mean cell
hemoglobin
concentration (g/dL)
33.1 ± 1.2 32.6 ± 1.1 32.8 (32.5, 33.1) 33.4 ± 1.1 33.6 ± 0.9 33.4 (33, 33.7) -0.6 (-1.1, -0.08) 0.024*
White cell count x
109/L
6.8 ± 1.7 6.4 ± 1.6 6.5 (6, 6.9) 6.9 ± 1.6 6.8 ± 1.8 6.7 (6.3, 7.2) -0.3 (-1, 0.5) 0.45
Platelet count x
109/L
246 ± 50 237 ± 53 233 (219, 247) 239 ± 41 244 ± 50 248 (235, 262) -15 (-36, 5) 0.14
Mean cell volume
(MCV) fL
89 ± 5 90 ± 6 90 (89, 91) 90 ± 4 90 ± 4 90 (89, 90) 0.7 (-0.5, 1.9) 0.27
Blood neutrophils x
109/L
3.9 ± 1.5 3.7 ± 1.3 3.8 (3.3, 4.2) 3.9 ± 1.1 3.9 ± 1.6 3.8 (3.4, 4.3) -0.09 (-0.7, 0.6) 0.79
Log10 blood
eosinophils x 109/L
-0.7 ± 0.2 -0.8 ± 0.2 -0.8 (-0.9, -0.7) -0.7 ± 0.3 -0.7 ± 0.2 -0.7 (-0.8, -0.6) -0.09 (-0.2, 0.02) 0.11
Log10 ALT U/L 1.4 ± 0.2 1.3 ± 0.3 1.3 (1.3, 1.4) 1.3 ±0.2 1.3 ±1.3 1.3 (1.3, 1.4) -0.02 (-0.09, 0.04) 0.49
Log10 GGT 1.41 ±0.25 1.31 ±0.27 1.30 (1.26, 1.33) 1.36 ± 0.16 1.36 ± 0.16 1.37 (1.33,
1.40)
-0.07 (-0.12, -0.024) 0.004*
Total bilirubin μmol/L 9.1 ± 3.6 9.7 ± 3.9 10.1 (9.1, 11.1) 10.1 ± 3.7 10.1 ± 3.7 9.84 (8.9, 10.8) 0.2 (-1.2, 1.7) 0.76
Total alkaline
phosphatase U/L
69.1 ± 21.1 63.3 ± 18.9 63.8 (61.2, 66.4) 72.4 ± 15.1 70.6 ± 11 70 (67.5, 72.6) -6.2 (-10.1, -2.4) 0.002*
Random glucose
mmol/L
5.2 ± 0.8 5.0 ± 0.9 5.1 (4.7, 5.4) 5.5 ± 1.1 5.4 ± 0.8 5.4 (5.1, 5.7) -0.3 (-0.8, 0.2) 0.21
*p value < 0.05
Values reported as arithmetic mean unless speciﬁed
± Standard deviation
The adjusted mean of the secondary outcomes at 12 weeks was compared between groups using ANCOVA including terms for baseline value, treatment
arm, inhaled corticosteroid use, age, gender, and height and expressed as the difference in the adjusted means with a 95% CI and p-value.
ALT- alanine aminotransferase. GGT- gamma glutamyl transferase. ANCOVA- analysis of covariance
doi:10.1371/journal.pone.0160257.t006
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To our knowledge, this is the largest and longest study of a PPAR-γ agonist in asthma per-
formed to date [16– 19]. A previously reported RCT compared rosiglitazone to inhaled corti-
costeroids in 46 current smokers with asthma (a group associated with poor response to
inhaled corticosteroids), and reported a trend toward a higher pre-bronchodilator FEV1 in
the group treated with rosiglitazone at 28 days (183 mL, 95% CI -1.0 to 367, p = 0.051) (18).
There was also an improvement in the forced expiratory flow between 25 and 75% of the
forced vital capacity after 28 days of treatment with rosiglitazone (FEF25-75 0.24 L/second,
95% CI 0.03 to 0.46, p = 0.03), but no statistically significant improvements in ACQ scores or
sputum cell counts [18]. A second RCT compared 28 days of treatment with rosiglitazone
with placebo in 32 adults with mild asthma and reported a 15% attenuation of the late asth-
matic reaction, with no change in the early asthmatic reaction compared to placebo. The
authors also reported no effect on airway hyper-responsiveness after allergen challenge or on
a panel of inflammatory markers [17]. Dixon and colleagues reported a 12 week RCT com-
paring pioglitazone (n = 23) to placebo (n = 19) in obese subjects with poorly controlled
moderate to severe asthma [19]. Using 30mg pioglitazone for 2 weeks increased to 45mg for
10 weeks there were no significant differences in the airway hyper-responsiveness to metha-
choline, FeNO or lung function between treatment and placebo. Recruitment was halted
early (as in our study) due to the impact of emerging safety concerns surrounding the poten-
tial risk of bladder cancer affecting recruitment, lack of efficacy signal and significant weight
gain in pioglitazone treated patients [19]. The thiazolidinediones are associated with signifi-
cant adverse effects when administered systemically and these studies support our conclusion
that systemic treatment with pioglitazone is not associated with beneficial effects on asthma
control.
Conclusion
We found no evidence to support the hypothesis that 12 weeks of treatment with the PPAR-γ
agonist pioglitazone improves asthma control or airway inflammation in individuals with mild
asthma. Opportunities to further investigate the potential anti-inflammatory effects of pioglita-
zone in more severe asthma are currently limited by safety considerations.
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